Hims & Hers Health, Inc. (HIMS) shares tumbled 19.0% to $18.58 as of November 10, 2026, a sharp decline from the prior close of $22.94. BestStocks flagged the session as a major change for HIMS. Below, we break down what changed for HIMS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
HIMS fell 19.0% to $18.57
Hims & Hers plunged 12.42% following third-quarter results released November 10, 2026 (per web sources). The company reported a surprise $33 million GAAP net loss (14¢ per share vs. consensus +6¢) and cut full-year guidance to $3.13–$3.15B revenue and $257–$277M Adjusted EBITDA, marking its third guidance reduction this year. Subscriber count fell ~100,000 sequentially to 2.8M, attributed to scaled-back U.S. weight-loss marketing; Q4 revenue guidance of $875–$895M also missed analyst consensus near $953M. Confirm actual Q4 2026 results and full-year earnings due 2027-02-22; monitor subscriber trends and any strategic updates on weight-loss treatment transitions.
This summary describes the catalyst and move as first detected on Nov 10, 2026, 9:32 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
What it means for Hims & Hers Health, Inc. investors
For Hims & Hers Health, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Earnings missed expectations; Sharp 19.0% decline — elevated risk. Wall Street's consensus price target sits at $31.06, implying +67.2% upside from $18.58. BestStocks rates the overall signal quality medium (75/100). With earnings roughly 104 days out, the next report is the most likely near-term test of the move.
HIMS price reaction
HIMS last traded at $18.58, down $4.36 (-19.01%) from the previous close of $22.94. The session traded on 3.4× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $18.58 and $30.64, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Hims & Hers Health, Inc. (HIMS)
▼Latest catalyst·a bearish counterpoint
The latest catalyst — a materially negative development — a bearish counterpoint that challenges the prevailing bullish analyst view.
The consensus analyst price target on Hims & Hers Health, Inc. (HIMS) is $31.06, 67.2% above the recent $18.58. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on HIMS line up.
▲ The bullish case
+Wall Street's consensus price target of $31.06 implies +67.2% upside from $18.58.
+The Street's most bullish target is $40.00 (+115.3%).
+Positive price momentum.
▼ The bearish case
−Earnings missed expectations.
−Sharp 19.0% decline — elevated risk.
−High volume 3.4x on decline — distribution signal.
−Hims & Hers shares fell 6.40% to $27.77 as multiple law firms (Kaplan Fox, Faruqi & Faruqi, and Kessler Topaz Meltzer & Check) issued class-action notices ahead of a November 2, 2026 securities fraud lawsuit deadline, per newsfilecorp.com and PR Newswire.
−Hims & Hers is down 6.02% to $27.92 following a securities fraud class action announcement by Globe Newswire regarding deceptive privacy and billing practices, part of a broader 14%+ stock decline tied to the litigation.
Bull vs bear balanceStrong Bearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Analyst expectations
Consensus target: $31+67.2%
= 4 maintains
Evercore ISI Group maintained In Line · 2026-11-10
Hims & Hers Health, Inc. (HIMS) reported EPS of –$0.14 vs. consensus estimate of $0.06 for Q3 FY2026, missing by 348.8%.
Material / Earnings2026-11-09-11.8%
Hims & Hers Health, Inc. (HIMS) moved -9.15% from $25.25 to $22.94 on 2026-11-09 after reporting Q3 FY2026 earnings that missed consensus significantly: the company reported EPS of -$0.14 versus an estimate of $0.06, a -348.80% surprise. Volume surged to 3.7x the 5-day average, and HIMS reached a new 30-day low.
Hims & Hers announced a direct distribution agreement with Eli Lilly to provide branded obesity treatments (Zepbound, Foundayo) on its platform, including $149 pill access options. Per Barron's and Investor's Business Daily, the deal puts Eli Lilly on parity with rival Novo Nordisk and addresses investor concerns about HIMS's competitive positioning in the GLP-1 market. The stock rose 7.32% to $25.82 on volume of 9.0M shares (1.14x normal for this time of day).
Hims & Hers shares fell 6.40% to $27.77 as multiple law firms (Kaplan Fox, Faruqi & Faruqi, and Kessler Topaz Meltzer & Check) issued class-action notices ahead of a November 2, 2026 securities fraud lawsuit deadline, per newsfilecorp.com and PR Newswire. Volume at 2.92M shares tracked near normal levels for the time of day.
HIMS rose 6.02% to $29.60 following a U.S. Department of Health and Human Services enforcement discretion policy announced October 28 that temporarily allows state-licensed compounding pharmacies and physicians to manufacture six specific peptides—including BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500—without immediate regulatory action (per Google AI Overview citing seekingalpha.com and globenewswire.com). The policy removes near-term regulatory uncertainty for Hims' compounded telehealth offerings. Volume of 8.9M shares was 1.17x the time-adjusted average, indicating normal participation.
Hims & Hers (HIMS) rose 6.39% to $29.95, reversing earlier pressure tied to an FTC lawsuit that sparked a securities class action filing (per PR Newswire). Volume of 4.56M shares ran 1.37x normal for this stage of the session, suggesting retail participation in the recovery.
Hims & Hers (HIMS) rose 6.01% to $29.39 intraday despite multiple class-action securities fraud lawsuits being announced by SBS Law, Pomerantz Law Firm, and Robbins Geller Rudman & Dowd LLP (per Globe Newswire and PR Newswire). Volume of 13.0M shares is 1.31x expected for this stage of the session—normal activity levels.
Hims & Hers is down 6.02% to $27.92 following a securities fraud class action announcement by Globe Newswire regarding deceptive privacy and billing practices, part of a broader 14%+ stock decline tied to the litigation. Volume is tracking at 0.85x normal for this point in the session, suggesting orderly selling without capitulation.
In-depth HIMS event analyses
Permanent, dated analyses of HIMS's most significant sessions.
Why did Hims & Hers Health, Inc. (HIMS) stock move?
HIMS tumbled 19.0% to $18.58. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did HIMS stock fall?
HIMS lost 19.01% ($4.36) versus the prior close of $22.94, last trading at $18.58 on 3.4× average volume.
When is Hims & Hers Health, Inc.'s next earnings date?
HIMS's next earnings report is estimated for 2027-02-22 — about 104 days away.
What is the analyst price target for HIMS?
The consensus analyst price target for HIMS is $31.06, about 67.2% above the current $18.58. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks HIMS
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared HIMS-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for HIMS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
